COHERUS BIOSCIENCES INC reports a Return on Equity (ROE) of -192.90%.

What is CHRS's dividend yield?

COHERUS BIOSCIENCES INC offers a dividend yield of 0.00%.

What is CHRS's Deepscope Quality Score?

Deepscope rates CHRS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CHRS?

Deepscope's AI Timing Score for CHRS is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CHRS belong to?

COHERUS BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

CHRS (NASDAQ) Stock Analysis | COHERUS BIOSCIENCES INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

CHRS

COHERUS BIOSCIENCES INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 1.45

-0.13 (-7.94%) Day Change

Watchlist Portfolio Compare Chart

0.50

D/E

-192.9%

ROE

-57.0%

ROA

0.00%

Div Yield

COHERUS BIOSCIENCES INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.45 Price -0.13 (-7.94%) Day Change	NEWS SCORE: 89

CHRS, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.45
PBV / Sector	2.89 / 4.63
Earning Per Share	-0.97

PE / Sector	N/A / 17.43
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	2.36 M GREAT
Average 1W Daily Value	1.35 M GREAT

Timing Factors

14%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-323.49 / 449.48
NPM Average (%) / Sector	-189.47 / -1,506.49
NPM Change Average (%) / Sector	-1,011.51 / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-57.01 / 30.58
ROA Average (%) / Sector	-43.01 / -347.17
ROA Change Average (%) / Sector	-326.30 / 5,125.52
ROE (%) / Sector	-192.90 / -3.58
ROE Average (%) / Sector	-31.66 / 40.65
ROE Change Average (%) / Sector	250.44 / 2,109.80 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

Registration Details

Analyze Date	2026-06-06 09:08:29
Symbol	CHRS
Name	COHERUS BIOSCIENCES INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	154.25 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	227.52 / 8,857.28

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065

Phone: 650 649 3530

Website: https://www.coherus.com

Employees: 145

Sector: Healthcare >> Biotechnology

Description: Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.